메디포스트

078160KOSDAQ

46.3 / 100

Reference Date: 2026-09-08

Financial Score14.0 / 40

News Sentiment19.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 8.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Medipost operates three main business segments: umbilical cord blood banking, stem cell therapeutics (Cartistem), and health functional foods. In 2024, the company achieved a record sales revenue of 70.7 billion won, driven by strong performance in its cord blood banking division, which holds the top market share domestically, and its stem cell therapeutics division expanding global clinical trials.

Number of Employees

684people

Average Salary

61.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

1.42Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

-34.23Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

33.95Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼66.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.2% (declining, 3yr)

Detailed News Sentiment

14 totalPositive 12Neutral 0Negative 2Average Sentiment Score 77.1

Positive
메디포스트, '카티스템' 장기 임상 데이터 공유...관절보존 치료 가능...
메디포스트의 '카티스템' 임상 데이터 공유로 관절 보존 치료 가능성이 높아져 긍정적인 시장 반응 예상.
Positive
메디포스트, 신임 사장에 민호성 전 삼성바이오 부사장 영입
메디포스트의 신임 사장 영입으로 리더십 강화 기대
Positive
메디포스트, 삼성바이오로직스 출신 민호성 대표 영입
메디포스트의 민호성 부사장 영입으로 각자대표 체제 구축, 해외 사업 강화 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 9,050Won52-week high 28,00052-week low 7,520

1-month return1.0Point

1m -8.12% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-14